• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Andrology >Luteinizing Hormone (LH)-Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal Glands.
【24h】

Luteinizing Hormone (LH)-Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal Glands.

机译：黄体生成激素（LH）-释放激素激动剂可降低前列腺癌患者的血清肾上腺雄激素水平：对LH对肾上腺的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recently, adrenal androgens have been targeted as key hormones for the development of castration-resistant prostate cancer therapeutics. Although circulating adrenal androgens originate mainly from the adrenal glands, the testes also supply about 10%. Although widely used in androgen deprivation medical castration therapy, the effect of luteinizing hormone-releasing hormone (LH-RH) agonist on adrenal androgens has not been fully studied. In this study, changes in testicular and adrenal androgen levels were measured and compared to adrenocorticotropic hormone levels. To assess the possible role of LH in the adrenal glands, immunohistochemical studies of the LH receptor in normal adrenal glands were performed. Forty-seven patients with localized or locally progressive prostate cancer were treated with LH-RH agonist with radiotherapy. Six months after initiation of treatment, testosterone, dihydrotestosterone, and estradiol levels were decreased by 90%-95%, and dehydroepiandrosterone-sulfate, dehydroepiandrosterone, and androstenedione levels were significantly decreased by 26%-40%. The suppressive effect of LH-RH agonist at 12 months was maintained. Adrenocorticotropic hormone levels showed an increasing trend at 6 months and a significant increase at 12 months. LH receptors were positively stained in the cortex cells of the reticular layer of the adrenal glands. The long-term LH-RH agonist treatment reduced adrenal-originated adrenal androgens. LH receptors in the adrenal cortex cells of the reticular layer might account for the underlying mechanism of reduced adrenal androgens.
机译：最近，肾上腺雄激素已被靶向作为去势抵抗性前列腺癌治疗剂开发的关键激素。尽管循环中的肾上腺雄激素主要来自肾上腺，但睾丸也可提供约10％。尽管广泛用于雄激素剥夺医学去势疗法中，但尚未充分研究黄体生成激素释放激素（LH-RH）激动剂对肾上腺雄激素的作用。在这项研究中，测量了睾丸和肾上腺雄激素水平的变化，并将其与促肾上腺皮质激素水平进行了比较。为了评估LH在肾上腺中的可能作用，进行了正常肾上腺中LH受体的免疫组织化学研究。 LH-RH激动剂通过放射疗法治疗了47例局部或局部进行性前列腺癌患者。开始治疗六个月后，睾丸激素，二氢睾丸激素和雌二醇水平降低了90％-95％，硫酸脱氢表雄酮，脱氢表雄酮和雄烯二酮的水平显着降低了26％-40％。维持LH-RH激动剂在12个月时的抑制作用。促肾上腺皮质激素水平在6个月时呈上升趋势，在12个月时显着上升。 LH受体在肾上腺网状层的皮质细胞中被阳性染色。长期的LH-RH激动剂治疗可减少源自肾上腺的肾上腺雄激素。网状层的肾上腺皮质细胞中的LH受体可能是肾上腺雄激素减少的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号